Chemstructure (Chemstructure)
Levetiracetam Solution
Product Images NDC 72162-2667
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72162-2667). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image Description (Fig1)
This text provides information for calculating the daily dose of medication based on the patient's weight. It also indicates how to convert the dose from milligrams to milliliters using the concentration of the medication.*
Fig2 (Fig2)
This text provides formulas to calculate CLer (renal clearance) based on age, weight, and serum creatinine levels. The first formula involves subtracting the age from 140 and then multiplying the result by the weight in kilograms. The second formula calculates the clearance rate using a specific multiplier based on gender and the serum creatinine level in milligrams per deciliter.*
Fig3 (Fig3)
Not available.*
Fig4 (Fig4)
This text shows a comparison of responder rates (> 50% reduction from baseline) in Study 1 between a placebo group (N=95) and two different doses of levetiracetam - 1000 mg/day (N=97) and 3000 mg/day (N=101). It indicates that the responder rate for the 3000 mg/day group was statistically significant compared to the placebo group.*
Fig5 (Fig5)
This text provides data on the Responder Rate (> 50% Reduction from Baseline) in Study 2: Period A for three groups - Placebo (N=111), Levetiracetam 1000 mg/day (N=106), and Levetiracetam 2000 mg/day (N=105). The percentages show the proportion of participants achieving the specified reduction in seizures. It also notes that the difference in responder rates for Levetiracetam versus placebo is statistically significant.*
Fig6 (Fig6)
The text provides the percentages of different groups in a study comparing the effectiveness of Levetiracetam at a dosage of 3000 mg/day versus a placebo. The study included a placebo group of 104 participants and a Levetiracetam group of 180 participants. The text indicates that the results were statistically significant compared to the placebo group.*
Fig7 (Fig7)
This is a table showing the responder rates for patients taking Levetiracetam and placebo as part of a research study. The responder rate for Levetiracetam is 44.6%, which is statistically significant compared to the placebo group. The percentages of patients responding to treatment are shown in the table for different response levels ranging from 0% to 50%.*
Fig8 (Fig8)
This text provides data on the Responder Rate for all patients aged 1 month to less than 4 years in Study 5, showing a 43.1% response rate for Levetiracetam compared to 19.6% for placebo. The comparison between the two groups was statistically significant.*
Fig9 (Fig9)
This is a description of Figure 6 from Study 7 which shows the Responder Rate, defined as a 50% reduction from baseline, in primary generalized tonic-clonic (PGTC) seizure frequency per week. The graph displays the percentage of patients who achieved this reduction using both a placebo and Levetiracetam. It is noted that Levetiracetam showed a statistically significant difference compared to the placebo group.*
Label (Lbl721622667)
This text provides information on a medication called Levetiracetam USP 100 mg per mL. The usual dosage instructions are available through scanning the Package Insert QR code. Pharmacists are advised to dispense the medication in a tightly sealed container with child-resistant closure and store it at 25°C (77°F). The medication should be kept out of reach of children. The medication is manufactured by Bryant Ranch Prepack, Inc. and Quagen Pharmaceuticals. Pharmacists are recommended to dispense with a Medication Guide for each patient. The medication is made in the USA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
